The cerebral vasculopathy of Fabry disease

Journal of the Neurological Sciences

Volumn 257, Issue 1-2, 2007, Pages 258-263

  Moore, David F ^a   Kaneski, Christine R ^b   Askari, Hasan ^b   Schiffmann, Raphael ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Atherosclerosis; Fabry disease; Glycolipid; Lysosomal disease; Stroke; Vasculopathy; X linked disorder

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSPHINGOLIPID;

ARTICLE; BRAIN BLOOD VESSEL; CEREBROVASCULAR DISEASE; DNA MODIFICATION; ENDOTHELIUM INJURY; FABRY DISEASE; FEMALE; HUMAN; MALE; PATHOGENESIS; PRIORITY JOURNAL; STROKE; X CHROMOSOME LINKED DISORDER;

ANTICOAGULANTS; BRAIN; CEREBRAL ARTERIES; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISORDERS; ENDOTHELIAL CELLS; FABRY DISEASE; GLYCOSPHINGOLIPIDS; HUMANS; INTRACRANIAL THROMBOSIS;

EID: 34249800685     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.01.053     Document Type: Article

References (37)

1. Anderson W.A. A case of angiokeratoma. Br J Dermatol 18 (1898) 113-117
2. Brown A., and Milne J. Diffuse angiokeratoma: report of two cases with diffuse skin changes, one with neurological symptoms and splenomegaly. Glasgow Med J 33 (1952) 361
3. Bethune J., Landrigan P., and Chipman C. Angiokeratoma corporis diffusum (Fabry's disease in two brothers). N Engl J Med 264 (1961) 1280
4. Rolfs A., Bottcher T., Zschiesche M., Morris P., Winchester B., Bauer P., et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366 (2005) 1794-1796
5. Mitsias P., and Levine S.R. Cerebrovascular complications of Fabry's disease. Ann Neurol 40 (1996) 8-17
6. Moore D.F., Altarescu G., Barker W.C., Patronas N.J., Herscovitch P., and Schiffmann R. White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 62 (2003) 231-240
7. Moore D.F., Ye F., Schiffmann R., and Butman J.A. Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am J Neuroradiol 24 (2003) 1096-1101
8. Moore D.F., Herscovitch P., and Schiffmann R. Selective arterial distribution of cerebral hyperperfusion in Fabry disease. J Neuroimaging 11 (2001) 303-307
9. Mendez M.F., Stanley T.M., Medel N.M., Li Z., and Tedesco D.T. The vascular dementia of Fabry's disease. Dement Geriatr Cogn Disord 8 (1997) 252-257
10. Liston E.H., Levine M.D., and Philippart M. Psychosis in Fabry disease and treatment with phenoxybenzamine. Arch Gen Psychiatry 29 (1973) 402-403
11. Morgan S.H., Rudge P., Smith S.J., Bronstein A.M., Kendall B.E., Holly E., et al. The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency)-investigation of symptomatic and presymptomatic patients. Q J Med 75 (1990) 491-507
12. Grewal R.P., and McLatchey S.K. Cerebrovascular manifestations in a female carrier of Fabry's disease. Acta Neurol Belg 92 (1992) 36-40
13. Moore D.F., Altarescu G., Ling G.S., Jeffries N., Frei K.P., Weibel T., et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 33 (2002) 525-531
14. Crutchfield K.E., Patronas N.J., Dambrosia J.M., Frei K.P., Banerjee T.K., Barton N.W., et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 50 (1998) 1746-1749
15. DeGraba T., Azhar S., Dignat-George F., Brown E., Boutiere B., Altarescu G., et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 47 (2000) 229-233
16. Moore D.F., Scott L.T., Gladwin M.T., Altarescu G., Kaneski C., Suzuki K., et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104 (2001) 1506-1512
17. Moore D.F., Altarescu G., Herscovitch P., and Schiffmann R. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol 2 (2002) 4
18. Moore D.F., Schiffmann R., and Ulug A.M. Elevated CNS average diffusion constant in Fabry disease. Acta Paediatr Suppl 91 (2002) 67-68
19. Moore D.F., Ye F., Brennan M.L., Gupta S., Barshop B.A., Steiner R.D., et al. Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J Magn Reson Imaging 20 (2004) 674-683
20. Altarescu G., Moore D.F., Pursley R., Campia U., Goldstein S., Bryant M., et al. Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 32 (2001) 1559-1562
21. Stemper B., and Hilz M.J. Postischemic cutaneous hyperperfusion in the presence of forearm hypoperfusion suggests sympathetic vasomotor dysfunction in Fabry disease. J Neurol 250 (2003) 970-976
22. Kalliokoski R.J., Kalliokoski K.K., Sundell J., Engblom E., Penttinen M., Kantola I., et al. Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease. J Inherit Metab Dis 28 (2005) 563-573
23. Takanashi J., Barkovich A.J., Dillon W.P., Sherr E.H., Hart K.A., and Packman S. T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease. AJNR Am J Neuroradiol 24 (2003) 916-921
24. Hilz M.J., Kolodny E.H., Brys M., Stemper B., Haendl T., and Marthol H. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 251 (2004) 564-570
25. Laurindo F.R., Pedro Mde A., Barbeiro H.V., Pileggi F., Carvalho M.H., Augusto O., et al. Vascular free radical release. Ex vivo and in vivo evidence for a flow-dependent endothelial mechanism. Circ Res 74 (1994) 700-709
26. Florian J.A., Kosky J.R., Ainslie K., Pang Z., Dull R.O., and Tarbell J.M. Heparan sulfate proteoglycan is a mechanosensor on endothelial cells. Circ Res 93 (2003) e136-e142
27. Wei E.P., Kontos H.A., and Beckman J.S. Mechanisms of cerebral vasodilation by superoxide, hydrogen peroxide, and peroxynitrite. Am J Physiol 271 (1996) H1262-H1266
28. Schiffmann R., Rapkiewicz A., Abu-Asab M., Ries M., Askari H., Tsokos M., et al. Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch (2005) 1-7
29. Bodary P.F., Shen Y., Vargas F.B., Bi X., Ostenso K.A., Gu S., et al. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 111 (2005) 629-632
30. Kaneski C.R., Moore D.F., Ries M., Zirzow G., and Schiffmann R. Myeloperoxidase predicts risk for vasculopathic events in Fabry disease. Neurology 67 (2006) 2045-2047
31. Altarescu G., Moore D.F., and Schiffmann R. Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology 64 (2005) 2148-2150
32. Schiffmann R., Kopp J.B., Austin III H.A., Sabnis S., Moore D.F., Weibel T., et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285 (2001) 2743-2749
33. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., et al. Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease. N Engl J Med 345 (2001) 9-16
34. Schiffmann R., Ries M., Timmons M., Flaherty J.T., and Brady R.O. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21 (2006) 345-354
35. Wilcox W.R., Banikazemi M., Guffon N., Waldek S., Lee P., Linthorst G.E., et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75 (2004) 65-74
36. Schiffmann R., Floeter M.K., Dambrosia J.M., Gupta S., Moore D.F., Sharabi Y., et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 28 (2003) 703-710
37. Schiffmann R, Askari H, Timmons T, Robinson C, Benko W, Brady RO, Ries M. Weekly Enzyme replacement therapy may slow decline of renal tunction in Fabry patients on long-term biweekly dosing. J Am Soc Nephrol, in press.